creatine and Disease Exacerbation studies

Research Excerpts

Excerpt	Relevance	Reference
"To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease."	9.24	The CREST-E study of creatine for Huntington disease: A randomized controlled trial. ( Bredlau, AL; Hersch, SM; Meyers, CM; Nahin, R; Oakes, D; Rosas, HD; Schifitto, G, 2017)
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease."	9.20	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015)
"We performed serial (1)H-MRSI examinations to assess intratumoral metabolite intensities in 16 patients receiving high-dose oral tamoxifen monotherapy for recurrent malignant glioma (WHO grade III or IV) as part of a phase II clinical trial."	9.13	Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. ( Arnold, DL; Assina, R; Caramanos, Z; Langleben, A; Leblanc, R; Preul, MC; Sankar, T; Villemure, JG, 2008)
"Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND)."	8.88	Creatine for amyotrophic lateral sclerosis/motor neuron disease. ( Bedlack, RS; Moore, DH; Pastula, DM, 2012)
"Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS)."	8.86	Creatine for amyotrophic lateral sclerosis/motor neuron disease. ( Bedlack, RS; Moore, DH; Pastula, DM, 2010)
"Creatine has a neuroprotective effect in mutant superoxide dismutase (G93A) transgenic mice, an animal model of motor neuron disease (MND)."	7.70	Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. ( Ikeda, K; Iwasaki, Y; Kinoshita, M, 2000)
"To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease."	5.24	The CREST-E study of creatine for Huntington disease: A randomized controlled trial. ( Bredlau, AL; Hersch, SM; Meyers, CM; Nahin, R; Oakes, D; Rosas, HD; Schifitto, G, 2017)
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease."	5.20	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015)
"We performed serial (1)H-MRSI examinations to assess intratumoral metabolite intensities in 16 patients receiving high-dose oral tamoxifen monotherapy for recurrent malignant glioma (WHO grade III or IV) as part of a phase II clinical trial."	5.13	Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. ( Arnold, DL; Assina, R; Caramanos, Z; Langleben, A; Leblanc, R; Preul, MC; Sankar, T; Villemure, JG, 2008)
"Our objective was to determine the effect of creatine monohydrate on disease progression in patients with amyotrophic lateral sclerosis (ALS)."	5.13	Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. ( Barohn, RJ; Bedlack, RS; Chapin, J; Dick, A; Gelinas, DF; Jackson, CE; King, RM; Lou, JS; Phillips, LH; Rosenfeld, J, 2008)
"We sought to measure the temporal evolution and spatial distribution of lesion macromolecules and small molecules (lactate, N-acetyl compounds, creatine, and choline) in stroke patients by using short echo time in vivo proton MR spectroscopy."	5.09	Spectroscopic assessment of alterations in macromolecule and small-molecule metabolites in human brain after stroke. ( Graham, GD; Hwang, JH; Prichard, JW; Rothman, DL, 2001)
"Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND)."	4.88	Creatine for amyotrophic lateral sclerosis/motor neuron disease. ( Bedlack, RS; Moore, DH; Pastula, DM, 2012)
"Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS)."	4.86	Creatine for amyotrophic lateral sclerosis/motor neuron disease. ( Bedlack, RS; Moore, DH; Pastula, DM, 2010)
"To evaluate the prognostic value of the cortical N-acetyl aspartate to creatine ratio (NAA/Cr) in early relapsing-remitting multiple sclerosis (RRMS)."	3.80	Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. ( Blinkenberg, M; Hanson, LG; Mathiesen, HK; Paulson, OB; Skimminge, A; Sorensen, PS; Wu, X, 2014)
" Primary central nervous system lymphoma (PCNSL) is a highly aggressive tumor responsive to high-dose methotrexate based regimens."	3.73	Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. ( Abrey, LE; DeAngelis, LM; Koutcher, JA; Lis, E; Panageas, KS; Raizer, JJ; Xu, S; Zakian, KL, 2005)
"Creatine has a neuroprotective effect in mutant superoxide dismutase (G93A) transgenic mice, an animal model of motor neuron disease (MND)."	3.70	Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. ( Ikeda, K; Iwasaki, Y; Kinoshita, M, 2000)
"Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life."	2.84	Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. ( Boyd, J; Li, R; Pérez, A; Ren, X; Wills, AM, 2017)
"Late infantile metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder that causes severe demyelination of the nervous system."	2.75	Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. ( Barton, NW; Fogh, J; Hanson, LG; i Dali, C; Lund, AM; Nair, N, 2010)
"Diabetic nephropathy is the leading cause of end-stage renal disease."	2.70	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001)
"However, an objective measure of disease progression and therapeutic response is sorely needed."	2.40	Biological markers in the diagnosis and treatment of ALS. ( Arnold, DL; Cashman, NR; Kalra, S, 1999)
"With respect to the severity of autosomal recessive polycystic kidney disease, there is a wide spectrum of phenotypic manifestations, ranging from stillbirths to mildly affected of phenotypic manifestations, ranging from stillbirths to mildly affected adults, while intrafamilial variability of the clinical picture is generally small with multiple allelism as the most likely genetic explanation."	2.39	Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. ( Deget, F; Rudnik-Schöneborn, S; Zerres, K, 1995)
"To investigate disease progression and aging, we utilized young (1 month old) and old (21-25 months old) mdx and wild-type tongue muscles."	1.91	Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. ( Chamberlain, JS; Ferretti, R; Lorena, MDSV; Matsumura, CY; Nagana Gowda, GA; Odom, GL; Santos, EKD, 2023)
"Disease progression was investigated at 4 time points, from 9 to 18 months of age, and in 4 regions: cortex, hippocampus, striatum, and thalamus."	1.72	Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022)
"From a total of 1,174 IgAN patients in a multicenter retrospective cohort analysis in Japan, 195 patients were treated by tonsillectomy combined with corticosteroid."	1.62	Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. ( Hirano, K; Kataoka, H; Kawamura, T; Koike, K; Maruyama, S; Matsuo, S; Matsuzaki, K; Moriyama, T; Nitta, K; Suzuki, Y; Yasuda, T; Yasuda, Y; Yokoo, T, 2021)
"Serum TP levels at delivery in the preeclampsia group (53 ± 7 g/L) were lower than in the control group (61 ± 4 g/L, P < 0."	1.56	Hypoproteinemia as a parameter of poor perinatal/neonatal outcomes in women with preeclampsia diagnosed as hypertension plus proteinuria. ( Akabane-Nakagawa, K; Chiba, K; Cho, K; Kawaguchi, S; Mayama, M; Morikawa, M; Saito, Y; Umazume, T; Watari, H, 2020)
"Bioenergetic failure is a feature of Alzheimer's disease (AD)."	1.40	Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease. ( Bazinet, RP; Francis, BM; Gupta, S; Maj, M; Mount, HT; Robinson, B; Song, BJ; Yang, J, 2014)
"Lumbrokinase treatment attenuated diabetic nephropathy in rats, possibly through increasing the activity of MMPs and the subsequent degradation of extracellular matrix."	1.39	Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats. ( Cheng, X; Ge, N; Li, S; Li, Y; Shao, M; Shen, J; Sun, H, 2013)
"Recently, the clinical spectrum of dominant optic atrophy has been extended to frequent syndromic forms, exhibiting various degrees of neurological and muscle impairments frequently found in mitochondrial diseases."	1.38	The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. ( Angebault, C; Bielicki, G; Boddaert, N; Brabet, P; Cazevieille, C; Chaix, B; Delettre, C; Gueguen, N; Hamel, CP; Lenaers, G; Mausset-Bonnefont, AL; Puel, JL; Renou, JP; Reynier, P; Rigau, V; Sarzi, E; Seveno, M; Wang, J, 2012)
"Fourteen patients with juvenile absence epilepsy with typical absence seizures and 10 healthy volunteer controls were included in this study."	1.36	A proton magnetic resonance spectroscopic study in juvenile absence epilepsy in early stages. ( Erdinc, O; Gumustas, OG; Kabay, SC; Karaman, HO; Ozden, H, 2010)
"Large variation in diabetic nephropathy prevalence remains and is associated with diabetes registry size, screening and treatment practices, suggesting that understanding this variation may help detect and better manage diabetic nephropathy."	1.36	Identifying additional patients with diabetic nephropathy using the UK primary care initiative. ( Cardwell, CR; Fogarty, DG; Hunter, SJ; Kee, F; Magee, GM; Murphy, MC; Savage, G, 2010)
"Cerebral fat embolism induced by a triolein emulsion resulted in no significant change in the major metabolites of the brain in the acute stage, except for an elevated lipid/Cr ratio, which suggests the absence of any significant hypoxic-ischemic changes in the lesions embolized using a fat emulsion."	1.35	Proton magnetic resonance spectroscopic findings of cerebral fat embolism induced by triolein emulsion in cats. ( Baik, SK; Chang, KH; Cho, BM; Choi, SH; Kim, DH; Kim, HJ; Kim, YW; Lee, JW; Lee, SH, 2008)
"Prion diseases are fatal chronic neurodegenerative diseases."	1.34	MRI and MRS alterations in the preclinical phase of murine prion disease: association with neuropathological and behavioural changes. ( Anthony, DC; Blamire, AM; Broom, KA; Griffin, JL; Lowe, JP; Perry, VH; Scott, H; Sibson, NR; Styles, P, 2007)
"However, diabetic patients with ESRD secondary to dNP were significantly younger than those with vNP."	1.33	Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy. ( Biesenbach, G; Janko, O; Pieringer, H; Schmekal, B, 2006)
"Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations."	1.32	Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003)
"Creatine treatment started at 6, 8, and 10 weeks of age, analogous to early, middle, and late stages of human HD, significantly extended survival at both the 6- and 8-week starting points."	1.32	Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. ( Beal, MF; Dedeoglu, A; Ferrante, KL; Ferrante, RJ; Hersch, SM; Kubilus, JK; Yang, L, 2003)
"Bladder cancer is the fourth most common malignant neoplasm in men and the tenth most common in women."	1.32	Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. ( Emerk, K; Mutlu, N; Turkeri, L, 2003)
"The fulminating form of subacute sclerosing panencephalitis is an extremely rare condition."	1.32	Subacute sclerosing panencephalitis with fulminating course: follow-up magnetic resonance spectroscopy (MRS) findings. ( Alkan, A; Aslan, M; Kutlu, R; Sarac, K; Sigirci, A; Yakinci, C, 2004)
"The diagnosis of gliomatosis cerebri with MR imaging is known to be difficult."	1.31	MR spectroscopy in gliomatosis cerebri. ( Bendszus, M; Burger, R; Klein, R; Schichor, C; Solymosi, L; Tonn, JC; Warmuth-Metz, M, 2000)
"Cystic kidney disease progression was assessed by measuring kidney size and fluid content and determining cyst scores."	1.31	Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. ( Aukema, HM; DiMarco, NM; Edmunds, JW; Jayapalan, S; Saboorian, MH, 2001)
"The metabolic disturbances indicate disease progression but are less pronounced than in older patients with hemimegalencephaly."	1.30	Proton magnetic resonance spectroscopy of linear nevus sebaceus syndrome. ( Christen, HJ; Frahm, J; Hanefeld, FA; Kruse, B; Pouwels, PJ, 1998)

Research

Studies (132)

Authors

Clinical Trials (25)

Trial Overview

Trial Outcomes

The Global Outcome Combined Information on Change From Baseline in Schwab England Activities of Daily Living, 39-Item Parkinson's Disease Questionnaire, Ambulatory Capacity, Symbol Digit Modalities, and Modified Rankin at 5 Years.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	14 (10.61)	18.2507
2000's	64 (48.48)	29.6817
2010's	49 (37.12)	24.3611
2020's	5 (3.79)	2.80

Authors	Studies
Muñoz-Moreno, E	1
Simões, RV	1
Tudela, R	1
López-Gil, X	1
Soria, G	1
Lorena, MDSV	1
Santos, EKD	1
Ferretti, R	1
Nagana Gowda, GA	1
Odom, GL	1
Chamberlain, JS	1
Matsumura, CY	1
Han, X	1
Xiao, Y	1
Tang, Y	1
Zheng, X	1
Anwar, M	1
Qin, W	1
Blicher, JU	1
Eskildsen, SF	1
Stærmose, TG	1
Møller, AT	1
Figlewski, K	1
Near, J	1
Morikawa, M	1
Mayama, M	1
Saito, Y	1
Akabane-Nakagawa, K	1
Umazume, T	1
Chiba, K	1
Kawaguchi, S	1
Cho, K	1
Watari, H	1
Moriyama, T	1
Kataoka, H	1
Nitta, K	1
Hirano, K	1
Matsuzaki, K	1
Yasuda, T	1
Yasuda, Y	1
Koike, K	1
Maruyama, S	1
Yokoo, T	1
Matsuo, S	2
Kawamura, T	1
Suzuki, Y	1
Shiga, Y	1
Nezu, T	1
Nakamori, M	1
Hosomi, N	1
Akiyama, Y	1
Tachiyama, K	1
Kamimura, T	1
Kinoshita, N	1
Hayashi, Y	1
Matsushima, H	1
Imamura, E	1
Aoki, S	1
Ueno, H	1
Ohshita, T	1
Wakabayashi, S	1
Yamasaki, F	1
Awai, K	1
Maruyama, H	1
Simon, DK	2
Wu, C	1
Tilley, BC	2
Lohmann, K	1
Klein, C	1
Payami, H	1
Wills, AM	3
Aminoff, MJ	2
Bainbridge, J	1
Dewey, R	1
Hauser, RA	1
Schaake, S	1
Schneider, JS	2
Sharma, S	1
Singer, C	2
Tanner, CM	2
Truong, D	1
Wei, P	1
Wong, PS	1
Yang, T	1
Kirov, II	1
Liu, S	1
Tal, A	1
Wu, WE	1
Davitz, MS	1
Babb, JS	1
Rusinek, H	1
Herbert, J	1
Gonen, O	1
Hersch, SM	2
Schifitto, G	1
Oakes, D	1
Bredlau, AL	1
Meyers, CM	1
Nahin, R	1
Rosas, HD	1
Li, R	1
Pérez, A	2
Ren, X	1
Boyd, J	2
Fedele, TA	1
Galdos-Riveros, AC	1
Jose de Farias e Melo, H	1
Magalhães, A	1
Maria, DA	1
Kantarci, K	4
Stromillo, ML	1
Giorgio, A	1
Rossi, F	1
Battaglini, M	1
Hakiki, B	1
Malentacchi, G	1
Santangelo, M	1
Gasperini, C	1
Bartolozzi, ML	1
Portaccio, E	1
Amato, MP	1
De Stefano, N	6
Bellenberg, B	1
Busch, M	1
Trampe, N	1
Gold, R	1
Chan, A	1
Lukas, C	1
Targosz-Gajniak, MG	1
Siuda, JS	1
Wicher, MM	1
Banasik, TJ	1
Bujak, MA	1
Augusciak-Duma, AM	1
Opala, G	1
Bruggers, CS	1
Moore, K	1
Francis, BM	1
Yang, J	1
Song, BJ	1
Gupta, S	1
Maj, M	1
Bazinet, RP	1
Robinson, B	1
Mount, HT	1
Bayer-Karpinska, A	1
Schwarz, F	1
Wollenweber, FA	1
Poppert, H	1
Boeckh-Behrens, T	1
Becker, A	1
Clevert, DA	1
Nikolaou, K	1
Opherk, C	1
Dichgans, M	1
Saam, T	1
Wu, X	1
Hanson, LG	2
Skimminge, A	1
Sorensen, PS	1
Paulson, OB	1
Mathiesen, HK	1
Blinkenberg, M	1
Gerber, LM	1
Mann, SJ	1
Chase, HS	1
Hirsch, JS	1
Mohan, S	1
Rao, MK	1
Radhakrishnan, J	1
Kieburtz, K	1
Elm, JJ	1
Babcock, D	1
Hauser, R	1
Ross, GW	1
Augustine, AH	1
Augustine, EU	1
Bodis-Wollner, IG	1
Cambi, F	1
Chou, K	1
Christine, CW	1
Cines, M	1
Dahodwala, N	1
Derwent, L	1
Dewey, RB	1
Hawthorne, K	1
Houghton, DJ	1
Kamp, C	1
Leehey, M	1
Lew, MF	1
Liang, GS	1
Luo, ST	1
Mari, Z	1
Morgan, JC	1
Parashos, S	1
Petrovitch, H	1
Rajan, S	1
Reichwein, S	1
Roth, JT	1
Shannon, KM	1
Simuni, T	1
Sudarsky, L	1
Umeh, CC	1
Williams, K	1
Zhou, L	1
Fan, Y	1
Almuqbel, M	1
Melzer, TR	1
Myall, DJ	1
MacAskill, MR	1
Pitcher, TL	1
Livingston, L	1
Wood, KL	1
Keenan, RJ	1
Dalrymple-Alford, JC	1
Anderson, TJ	1
Norouzi, J	1
Yadollahpour, A	1
Mirbagheri, SA	1
Mazdeh, MM	1
Hosseini, SA	1
Löbel, U	1
Hwang, S	1
Edwards, A	1
Li, Y	2
Li, X	1
Broniscer, A	1
Patay, Z	1
Drew, L	1
Sankar, T	1
Caramanos, Z	1
Assina, R	1
Villemure, JG	1
Leblanc, R	1
Langleben, A	1
Arnold, DL	7
Preul, MC	1
Rosenfeld, J	1
King, RM	1
Jackson, CE	1
Bedlack, RS	3
Barohn, RJ	1
Dick, A	1
Phillips, LH	1
Chapin, J	1
Gelinas, DF	1
Lou, JS	1
Bonello, L	1
De Labriolle, A	1
Roy, P	1
Steinberg, DH	1
Okabe, T	1
Pinto Slottow, TL	1
Xue, Z	1
Torguson, R	1
Suddath, WO	1
Satler, LF	1
Kent, KM	1
Pichard, AD	1
Lindsay, J	1
Waksman, R	1
Damman, K	1
van Veldhuisen, DJ	1
Navis, G	1
Voors, AA	1
Hillege, HL	1
Baik, SK	1
Kim, YW	1
Kim, HJ	1
Lee, JW	1
Cho, BM	1
Kim, DH	1
Choi, SH	1
Lee, SH	1
Chang, KH	1
Pyra, T	1
Hui, B	1
Hanstock, C	1
Concha, L	1
Wong, JC	1
Beaulieu, C	1
Johnston, W	1
Kalra, S	2
Imamura, A	1
Miyajima, H	1
Ito, R	1
Orii, KO	1
Peters, HP	1
van den Brand, JA	1
Wetzels, JF	2
Weigand, SD	2
Przybelski, SA	1
Shiung, MM	1
Whitwell, JL	1
Negash, S	1
Knopman, DS	2
Boeve, BF	3
O'Brien, PC	3
Petersen, RC	3
Jack, CR	3
Pilatus, U	2
Lais, C	1
Rochmont, Adu M	1
Kratzsch, T	1
Frölich, L	1
Maurer, K	1
Zanella, FE	1
Lanfermann, H	2
Pantel, J	1
Kabay, SC	1
Gumustas, OG	1
Karaman, HO	1
Ozden, H	1
Erdinc, O	1
Jickling, G	1
Salam, A	1
Mohammad, A	1
Hussain, MS	1
Scozzafava, J	1
Nasser, AM	1
Jeerakathil, T	1
Shuaib, A	1
Camicioli, R	1
Hattingen, E	1
Delic, O	1
Franz, K	1
Raab, P	1
Gerlach, R	1
Matsusue, E	1
Fink, JR	1
Rockhill, JK	1
Ogawa, T	1
Maravilla, KR	1
Qian, J	1
Herrera, JJ	1
Narayana, PA	1
Acosta, ML	1
Shin, YS	1
Ready, S	1
Fletcher, EL	1
Christie, DL	1
Kalloniatis, M	1
Tan, JC	1
Pastula, DM	2
Moore, DH	2
Magee, GM	1
Hunter, SJ	1
Cardwell, CR	1
Savage, G	1
Kee, F	1
Murphy, MC	1
Fogarty, DG	1
i Dali, C	1
Barton, NW	1
Fogh, J	1
Nair, N	1
Lund, AM	1
Kim, JH	1
Choi, BS	1
Jung, C	1
Chang, Y	1
Kim, S	1
Astor, BC	4
Matsushita, K	4
Gansevoort, RT	4
van der Velde, M	4
Woodward, M	4
Levey, AS	3
Jong, PE	1
Coresh, J	4
de Jong, PE	2
El-Nahas, M	2
Eckardt, KU	2
Kasiske, BL	2
Wright, J	1
Appel, L	1
Greene, T	1
Levin, A	1
Djurdjev, O	1
Wheeler, DC	1
Landray, MJ	1
Townend, JN	1
Emberson, J	1
Clark, LE	1
Macleod, A	1
Marks, A	1
Ali, T	1
Fluck, N	1
Prescott, G	1
Smith, DH	1
Weinstein, JR	1
Johnson, ES	1
Thorp, ML	1
Blankestijn, PJ	1
van Zuilen, AD	1
Menon, V	1
Sarnak, M	1
Beck, G	1
Kronenberg, F	1
Kollerits, B	1
Froissart, M	1
Stengel, B	1
Metzger, M	1
Remuzzi, G	2
Ruggenenti, P	1
Perna, A	1
Heerspink, HJ	1
Brenner, B	1
de Zeeuw, D	2
Rossing, P	1
Parving, HH	2
Auguste, P	2
Veldhuis, K	2
Wang, Y	2
Camarata, L	2
Thomas, B	2
Manley, T	2
Levey, A	2
de Jong, P	1
Ninomiya, T	1
Chalmers, J	1
Macmahon, S	1
Tonelli, M	1
Hemmelgarn, B	1
Sacks, F	1
Curhan, G	1
Collins, AJ	1
Li, S	2
Chen, SC	1
Hawaii Cohort, KP	1
Lee, BJ	1
Ishani, A	1
Neaton, J	1
Svendsen, K	1
Mann, JF	1
Yusuf, S	1
Teo, KK	1
Gao, P	1
Nelson, RG	1
Knowler, WC	1
Bilo, HJ	1
Joosten, H	1
Kleefstra, N	1
Groenier, KH	1
Johnson, KR	1
Akira, K	1
Masu, S	1
Imachi, M	1
Mitome, H	1
Hashimoto, T	1
Nicolasjilwan, M	1
Lopes, MB	1
Larner, J	1
Wintermark, M	1
Schiff, D	1
Yu, MK	1
Ye, W	1
Cherney, DZ	1
Scholey, JW	1
Daneman, D	1
Dunger, DB	1
Dalton, RN	1
Moineddin, R	1
Mahmud, FH	1
Dekker, R	1
Elia, Y	1
Sochett, E	1
Reich, HN	1
Wadman, RI	1
Bosboom, WM	1
van der Pol, WL	1
van den Berg, LH	2
Wokke, JH	2
Iannaccone, ST	1
Vrancken, AF	1
Lim, TS	1
Hong, YH	1
Lee, HY	1
Choi, JY	1
Kim, HS	1
Moon, SY	1
Lucarelli, G	1
Ditonno, P	1
Bettocchi, C	1
Grandaliano, G	1
Gesualdo, L	1
Selvaggi, FP	1
Battaglia, M	1
Ikeda, K	2
Murata, K	1
Kawase, Y	1
Kawabe, K	1
Kano, O	1
Yoshii, Y	1
Takazawa, T	1
Hirayama, T	1
Iwasaki, Y	2
Wang, PS	1
Chen, HC	1
Wu, HM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426]	Phase 3	553 participants (Actual)	Interventional	2009-09-30	Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.)
A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)[NCT00449865]	Phase 3	1,741 participants (Actual)	Interventional	2007-03-31	Terminated (stopped due to Futility)
Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477]	Phase 1	150 participants (Anticipated)	Interventional	2016-09-30	Enrolling by invitation
Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias[NCT04202770]		300 participants (Anticipated)	Interventional	2019-12-01	Suspended (stopped due to Pending COVID-19 pandemic; pending status of product development)
Carotid Plaque Imaging in Acute Stroke[NCT01284933]		234 participants (Actual)	Observational	2011-02-28	Completed
Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667]	Phase 4	220 participants (Anticipated)	Interventional	2017-04-10	Recruiting
MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans[NCT02729428]		71 participants (Actual)	Observational	2016-04-30	Completed
Multi-paramEtric Imaging to Assess Treatment REsponse After Stereotactic Radiosurgery of Brain Metastases[NCT04626206]		12 participants (Anticipated)	Observational	2020-12-31	Not yet recruiting
A Phase I/II, Open Labeled, Monocentric Study of Direct Intracranial Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human ARSA cDNA to Children With Metachromatic Leukodystrophy.[NCT01801709]	Phase 1/Phase 2	5 participants (Anticipated)	Interventional	2014-06-30	Active, not recruiting
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study[NCT03480568]	Phase 3	20 participants (Anticipated)	Interventional	2018-05-01	Recruiting
Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes[NCT01581476]	Phase 3	443 participants (Actual)	Interventional	2009-01-31	Completed
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]	Phase 3	609 participants (Actual)	Interventional	2008-03-31	Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study[NCT01411150]	Phase 2	38 participants (Actual)	Interventional	2009-05-31	Completed
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability[NCT01411163]	Phase 2	24 participants (Actual)	Interventional	2010-04-30	Completed
Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995]	Phase 2	64 participants (Actual)	Interventional	2007-12-31	Completed
Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD[NCT01412151]	Phase 2	10 participants (Actual)	Interventional	2005-04-30	Completed
Sjogren-Larsson Syndrome: A Longitudinal Study of Natural History, Clinical Variation and Evaluation of Biochemical Markers[NCT01971957]		20 participants (Actual)	Observational [Patient Registry]	2013-04-01	Completed
An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS[NCT02587806]	Phase 1/Phase 2	69 participants (Anticipated)	Interventional	2015-02-28	Recruiting
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitti[NCT02587715]	Phase 1/Phase 2	69 participants (Anticipated)	Interventional	2015-02-28	Recruiting
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitti[NCT02418325]	Phase 1/Phase 2	69 participants (Anticipated)	Interventional	2015-02-28	Terminated (stopped due to Lack of funding)
Creatine Monohydrate Use for Preventing Altitude Induced Depression[NCT03433651]	Phase 4	0 participants (Actual)	Interventional	2019-01-01	Withdrawn (stopped due to Unable to locate grant funding.)
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-25	Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347]	Phase 3	1,513 participants (Actual)	Interventional	1996-05-31	Completed
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695]	Phase 4	40 participants (Anticipated)	Interventional	2021-07-21	Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]		141 participants (Actual)	Observational	2013-11-07	Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

All outcomes were coded such that higher scores indicated worse outcomes. Patients were ranked on each outcome and their ranks were summed (summed-ranks). Higher summed ranks (range, 5-4775) indicate worse outcomes. The mean summed ranks were compared by treatment group by a global statistical test (GST). (NCT00449865)
Timeframe: Change from baseline to 5 YEARS

Change in Behavioral Frequency Score From Baseline to Month 60

Intervention	summed-ranks (Mean)
Placebo	2360
Creatine	2414

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	1.39
B - Placebo	1.43

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Functional Checklist Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	4.29
B - Placebo	5.06

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Change in Independence Scale Score From Baseline to Month 60

Intervention	units on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day	-7.93
B - Placebo	-8.02

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Intervention	units on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day	-26.30
B - Placebo	-24.86

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Interference From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-14.21
B - Placebo	-14.51

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-7.57
B - Placebo	-8.61

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-15.25
B - Placebo	-19.13

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-10.95
B - Placebo	-11.36

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Change in Total Motor Score From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-4.53
B - Placebo	-4.76

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Change in Verbal Fluency Test From Baseline to Month 60

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	18.06
B - Placebo	19.18

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

Intervention	units on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day	-5.07
B - Placebo	-4.47

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Number Completing Study at Assigned Dosage Level

Time to a Three-Point Decline in TFC Score or Death

Intervention	rank (Mean)
A - Coenzyme Q10 2400 mg/Day	303.3
B - Placebo	306.7

Intervention	participants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day	98
B - Placebo	108

Time to a Two-Point Decline in TFC Score or Death

Intervention	days to event (Median)
A - Coenzyme Q10 2400 mg/Day	917
B - Placebo	911

Tolerability

Intervention	days to event (Median)
A - Coenzyme Q10 2400 mg/Day	553
B - Placebo	549

Proportion of subjects able to complete treatment (NCT01412151)
Timeframe: 306 Weeks

Article	Year
The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology, 2017, Aug-08, Volume: 89, Issue:6 Topics: Australia; Creatine; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hu	2017
Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. Journal of neurology, 2017, Volume: 264, Issue:8 Topics: Age Factors; Antiparkinson Agents; Creatine; Disease Progression; Dopamine Agents; Double-Blind Meth	2017
1H-magnetic resonance spectroscopy in diffuse and focal cervical cord lesions in multiple sclerosis. European radiology, 2013, Volume: 23, Issue:12 Topics: Adult; Analysis of Variance; Aspartic Acid; Cervical Vertebrae; Creatine; Cross-Sectional Studies; D	2013
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA, 2015, Feb-10, Volume: 313, Issue:6 Topics: Aged; Antiparkinson Agents; Creatine; Disease Progression; Double-Blind Method; Drug Therapy, Combin	2015
Randomized trial of erhuangfang for relapsing multiple sclerosis. Neurological research, 2015, Volume: 37, Issue:7 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Aspartic Acid; Brain; Creatine; Disability Evaluation;	2015
Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. Journal of neuro-oncology, 2008, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aspartic Acid; Brain Neoplasms; Choline; Creatine; Dis	2008
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2008, Volume: 9, Issue:5 Topics: Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Creatine; Disease Progression; Double-Blind Method;	2008
Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology, 2010, Nov-23, Volume: 75, Issue:21 Topics: Aspartic Acid; Biomarkers; Brain; Child, Preschool; Choline; Cognition; Creatine; Disease Progressio	2010
Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:10 Topics: Adolescent; Albuminuria; Biomarkers; Chemokines; Child; Creatine; Cytokines; Diabetes Mellitus, Type	2012
Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. Journal of neurology, 2003, Volume: 250, Issue:2 Topics: Adult; Aspartic Acid; Axons; Body Water; Brain Chemistry; Cohort Studies; Creatine; Disease Progress	2003
A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Annals of neurology, 2003, Volume: 53, Issue:4 Topics: Aged; Amyotrophic Lateral Sclerosis; Creatine; Disease Progression; Double-Blind Method; Female; Hum	2003
The use of statistical MUNE in a multicenter clinical trial. Muscle & nerve, 2004, Volume: 30, Issue:4 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Cell Count; Creatine; Data Interpretation, Statist	2004
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study. Dementia and geriatric cognitive disorders, 2008, Volume: 25, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord	2008
Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney international. Supplement, 1997, Volume: 63 Topics: Carbon; Creatine; Creatinine; Diet, Protein-Restricted; Disease Progression; Humans; Kidney Failure,	1997
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre	2001
Longitudinal changes of metabolites in frontal lobes after hemorrhagic stroke of basal ganglia: a proton magnetic resonance spectroscopy study. Stroke, 2001, Volume: 32, Issue:10 Topics: Aged; Aged, 80 and over; Aspartic Acid; Basal Ganglia Hemorrhage; Creatine; Disease Progression; Fem	2001
Spectroscopic assessment of alterations in macromolecule and small-molecule metabolites in human brain after stroke. Stroke, 2001, Dec-01, Volume: 32, Issue:12 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain; Choline; Creatine; Disease Progression; Female;	2001

Article	Year
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. Scientific reports, 2022, 10-10, Volume: 12, Issue:1 Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G	2022
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. Skeletal muscle, 2023, 09-13, Volume: 13, Issue:1 Topics: Acetic Acid; Alanine; Animals; Creatine; Disease Progression; Glycerol; Isoleucine; Methionine; Mice	2023
Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome. Clinical and experimental medicine, 2019, Volume: 19, Issue:4 Topics: Adult; China; Creatine; Disease Progression; Female; Glomerular Filtration Rate; Glomerulonephritis,	2019
Short echo-time Magnetic Resonance Spectroscopy in ALS, simultaneous quantification of glutamate and GABA at 3 T. Scientific reports, 2019, 11-26, Volume: 9, Issue:1 Topics: Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Choline; Creatine; Disease Progression;	2019
Hypoproteinemia as a parameter of poor perinatal/neonatal outcomes in women with preeclampsia diagnosed as hypertension plus proteinuria. Pregnancy hypertension, 2020, Volume: 21 Topics: Adult; Case-Control Studies; Creatine; Disease Progression; Female; Gestational Age; Humans; Pre-Ecl	2020
Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. Clinical and experimental nephrology, 2021, Volume: 25, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Combined Modality Therapy; Creatine; Disease Progression; Female; Gl	2021
Utility of Magnetic Resonance Spectroscopy for the Progression of Neurological Symptoms in Lenticulostriate Artery Territory Infarction. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2021, Volume: 30, Issue:6 Topics: Aged; Aged, 80 and over; Basal Ganglia Cerebrovascular Disease; Biomarkers; Brain Infarction; Cholin	2021
Caffeine, creatine, GRIN2A and Parkinson's disease progression. Journal of the neurological sciences, 2017, Apr-15, Volume: 375 Topics: Aged; Caffeine; Creatine; Disease Progression; Female; Gene-Environment Interaction; Genetic Predisp	2017
Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging. Human brain mapping, 2017, Volume: 38, Issue:8 Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Cross-Sectional Studies; Disease Progression; Female	2017
Prognostic relationship of metabolic profile obtained of melanoma B16F10. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:2 Topics: Animals; Apoptosis; Biomarkers, Tumor; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation;	2013
Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, Jun-04, Volume: 80, Issue:23 Topics: Adult; Aspartic Acid; Axons; Brain; Choline; Creatine; Disease Progression; Female; Humans; Magnetic	2013
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. Journal of the neurological sciences, 2013, Dec-15, Volume: 335, Issue:1-2 Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D	2013
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. Journal of the neurological sciences, 2013, Dec-15, Volume: 335, Issue:1-2 Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D	2013
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. Journal of the neurological sciences, 2013, Dec-15, Volume: 335, Issue:1-2 Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D	2013
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia. Journal of the neurological sciences, 2013, Dec-15, Volume: 335, Issue:1-2 Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D	2013
Magnetic resonance imaging spectroscopy in pediatric atypical teratoid rhabdoid tumors of the brain. Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:6 Topics: Brain; Brain Neoplasms; Child, Preschool; Choline; Chromosomal Proteins, Non-Histone; Creatine; Diag	2014
Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2014, Volume: 39, Issue:2 Topics: Adenosine Triphosphate; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cardiolip	2014
The carotid plaque imaging in acute stroke (CAPIAS) study: protocol and initial baseline data. BMC neurology, 2013, Dec-13, Volume: 13 Topics: Aged; Carotid Stenosis; Cerebral Cortex; Cognition Disorders; Cohort Studies; Creatine; Disease Prog	2013
Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. Neurological research, 2014, Volume: 36, Issue:8 Topics: Adult; Aspartic Acid; Cerebral Cortex; Creatine; Disability Evaluation; Disease Progression; Female;	2014
Development of a model to estimate 24-hour urinary creatinine excretion. Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:5 Topics: Biomarkers; Circadian Rhythm; Creatine; Disease Progression; Female; Follow-Up Studies; Humans; Hype	2014
Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study. BMC nephrology, 2014, Nov-27, Volume: 15 Topics: Acidosis; Aged; Aged, 80 and over; Anemia; Bicarbonates; Calcium; Case-Control Studies; Creatine; Di	2014
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. Parkinsonism & related disorders, 2016, Volume: 22 Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf	2016
Predicting Renal Failure Progression in Chronic Kidney Disease Using Integrated Intelligent Fuzzy Expert System. Computational and mathematical methods in medicine, 2016, Volume: 2016 Topics: Adult; Aged; Artificial Intelligence; Blood Pressure; Calcium; Creatine; Disease Progression; Expert	2016
Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies. Neuroradiology, 2016, Volume: 58, Issue:10 Topics: Adolescent; Aging; Aspartic Acid; Biomarkers, Tumor; Brain Stem; Brain Stem Neoplasms; Child; Child,	2016
Two hundred steps. Nature, 2016, 10-27, Volume: 538, Issue:7626 Topics: alpha-Synuclein; Creatine; Deep Brain Stimulation; Disease Progression; Dopamine; Fetal Tissue Trans	2016
Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. The American journal of cardiology, 2008, Sep-01, Volume: 102, Issue:5 Topics: Acute Disease; Aged; Confidence Intervals; Coronary Angiography; Coronary Disease; Creatine; Disease	2008
Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European journal of heart failure, 2008, Volume: 10, Issue:10 Topics: Acute-Phase Proteins; Albumins; Case-Control Studies; Chronic Disease; Creatine; Disease Progression	2008
Proton magnetic resonance spectroscopic findings of cerebral fat embolism induced by triolein emulsion in cats. Acta radiologica (Stockholm, Sweden : 1987), 2008, Volume: 49, Issue:10 Topics: Animals; Aspartic Acid; Brain; Cats; Choline; Contrast Media; Creatine; Disease Models, Animal; Dise	2008
Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2010, Volume: 11, Issue:1-2 Topics: Amyotrophic Lateral Sclerosis; Aspartic Acid; Choline; Creatine; Diffusion Tensor Imaging; Disease P	2010
Serial MR imaging and 1H-MR spectroscopy in monozygotic twins with Tay-Sachs disease. Neuropediatrics, 2008, Volume: 39, Issue:5 Topics: Aspartic Acid; Basal Ganglia; Brain; Cerebral Cortex; Child, Preschool; Choline; Corpus Callosum; Cr	2008
Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy. The Netherlands journal of medicine, 2009, Volume: 67, Issue:2 Topics: Adolescent; Adult; Aged; Alpha-Globulins; beta 2-Microglobulin; Biomarkers; Creatine; Disease Progre	2009
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology, 2009, Apr-28, Volume: 72, Issue:17 Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Biomarkers; Brain; Cerebrovascular Disorders; Cogni	2009
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry research, 2009, Jul-15, Volume: 173, Issue:1 Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De	2009
A proton magnetic resonance spectroscopic study in juvenile absence epilepsy in early stages. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2010, Volume: 14, Issue:3 Topics: Adolescent; Aspartic Acid; Brain; Child; Choline; Creatine; Disease Progression; Down-Regulation; El	2010
Circulating endothelial progenitor cells and age-related white matter changes. Stroke, 2009, Volume: 40, Issue:10 Topics: Age Distribution; Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Brain; C-Reactive Protein;	2009
(1)H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurological research, 2010, Volume: 32, Issue:6 Topics: Adult; Aged; Brain Neoplasms; Choline; Creatine; Disease Progression; Disease-Free Survival; Female;	2010
Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology, 2010, Volume: 52, Issue:4 Topics: Adult; Aspartic Acid; Blood Volume; Brain; Brain Neoplasms; Cerebrovascular Circulation; Choline; Cr	2010
Neuronal and axonal degeneration in experimental spinal cord injury: in vivo proton magnetic resonance spectroscopy and histology. Journal of neurotrauma, 2010, Volume: 27, Issue:3 Topics: Animals; Aspartic Acid; Choline; Creatine; Disease Models, Animal; Disease Progression; Gliosis; Imm	2010
Retinal metabolic state of the proline-23-histidine rat model of retinitis pigmentosa. American journal of physiology. Cell physiology, 2010, Volume: 298, Issue:3 Topics: Adenosine Triphosphate; Age Factors; Animals; Apoptosis; Ca(2+) Mg(2+)-ATPase; Coumaric Acids; Creat	2010
Chronic hepatitis C and chronic kidney disease. Digestive diseases and sciences, 2010, Volume: 55, Issue:5 Topics: Creatine; Disease Progression; Global Health; Glomerular Filtration Rate; Hepatitis C, Chronic; Huma	2010
Identifying additional patients with diabetic nephropathy using the UK primary care initiative. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:12 Topics: Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progre	2010
Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt-Jakob disease: correlation with clinical course. Neuroradiology, 2011, Volume: 53, Issue:12 Topics: Aged; Aspartic Acid; Biomarkers; Brain; Choline; Creatine; Creutzfeldt-Jakob Syndrome; Diffusion Mag	2011
Strengths and weaknesses of renal markers as risk factors and surrogate markers. Kidney international, 2011, Volume: 79, Issue:12 Topics: Albuminuria; Biomarkers; Cardiovascular Diseases; Creatine; Disease Progression; Evidence-Based Medi	2011
A metabonomic study of biochemical changes characteristic of genetically hypertensive rats based on (1)H NMR spectroscopic urinalysis. Hypertension research : official journal of the Japanese Society of Hypertension, 2012, Volume: 35, Issue:4 Topics: Animals; Citric Acid; Creatine; Disease Progression; Hippurates; Hypertension; Magnetic Resonance Sp	2012
Subependymal seeding of low-grade oligodendroglial neoplasms: a case series. Journal of neuro-oncology, 2012, Volume: 108, Issue:1 Topics: Adult; Aspartic Acid; Creatine; Disease Progression; Ependyma; Fourth Ventricle; Glioma; Humans; Iso	2012
The imaging diagnosis and prognosis assessment of patients with midbrain injury in the acute phase of craniocerebral injury. Acta neurochirurgica. Supplement, 2012, Volume: 114 Topics: Adolescent; Adult; Aspartic Acid; Child; Choline; Craniocerebral Trauma; Creatine; Disease Progressi	2012
Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy. Dementia and geriatric cognitive disorders, 2012, Volume: 33, Issue:2-3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Disease Pr	2012
Delayed relief of ureteral obstruction is implicated in the long-term development of renal damage and arterial hypertension in patients with unilateral ureteral injury. The Journal of urology, 2013, Volume: 189, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Chemokine CCL2; Child; Child	2013
Relationship between cervical cord 1H-magnetic resonance spectroscopy and clinoco-electromyographic profile in amyotrophic lateral sclerosis. Muscle & nerve, 2013, Volume: 47, Issue:1 Topics: Amyotrophic Lateral Sclerosis; Cervical Vertebrae; Choline; Creatine; Disease Progression; Electromy	2013
Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6. PloS one, 2012, Volume: 7, Issue:10 Topics: Adult; Age of Onset; Aged; Aspartic Acid; Case-Control Studies; Cerebellum; Creatine; Disease Progre	2012
The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 12 Topics: Acoustic Stimulation; Age Factors; Aging, Premature; Animals; Aspartic Acid; Chi-Square Distribution	2012
Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats. Diabetes research and clinical practice, 2013, Volume: 100, Issue:1 Topics: Animals; Blotting, Western; Collagen Type IV; Creatine; Diabetes Mellitus, Experimental; Diabetic Ne	2013
Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. Journal of neurology, 2002, Volume: 249, Issue:7 Topics: Adult; Aspartic Acid; Atrophy; Creatine; Disease Progression; Female; Humans; Magnetic Resonance Spe	2002
Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 304, Issue:1 Topics: Animals; Creatine; Disease Progression; Electrophysiology; Insulin-Like Growth Factor I; Ion Channel	2003
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. Experimental neurology, 2003, Volume: 179, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of neurochemistry, 2003, Volume: 85, Issue:6 Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine	2003
Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. Clinical chemistry and laboratory medicine, 2003, Volume: 41, Issue:8 Topics: Biomarkers, Tumor; Creatine; Data Interpretation, Statistical; Disease Progression; Female; Fibronec	2003
Pantothenate kinase-associated neurodegeneration: MR imaging, proton MR spectroscopy, and diffusion MR imaging findings. AJNR. American journal of neuroradiology, 2003, Volume: 24, Issue:8 Topics: Adolescent; Aspartic Acid; Brain; Cerebellar Nuclei; Choline; Creatine; Diagnosis, Differential; Dif	2003
Alexander disease with serial MRS and a new mutation in the glial fibrillary acidic protein gene. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Acidosis, Respiratory; Alexander Disease; Basal Ganglia; Choline; Creatine; Disease Progression; DNA	2003
Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. Journal of the American College of Cardiology, 2003, Nov-05, Volume: 42, Issue:9 Topics: Adult; Cardiomyopathy, Dilated; Creatine; Disease Progression; Female; Humans; Image Processing, Com	2003
A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS. BMC neuroscience, 2004, Mar-05, Volume: 5 Topics: Acute Disease; AIDS Dementia Complex; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creat	2004
Leukoencephalopathy, cerebral calcifications, and cysts: new observations. Neurology, 2004, Apr-13, Volume: 62, Issue:7 Topics: Adolescent; Aspartic Acid; Brain; Brain Diseases; Calcinosis; Central Nervous System Cysts; Child; C	2004
MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR. American journal of neuroradiology, 2004, Volume: 25, Issue:4 Topics: Adolescent; Adult; Aspartic Acid; Brain; Cerebral Ventricles; Child; Child, Preschool; Choline; Crea	2004
Subacute sclerosing panencephalitis with fulminating course: follow-up magnetic resonance spectroscopy (MRS) findings. Journal of child neurology, 2004, Volume: 19, Issue:3 Topics: Aspartic Acid; Brain; Cerebral Cortex; Child, Preschool; Choline; Creatine; Diagnosis, Differential;	2004
Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. Journal of neurosurgery, 2004, Volume: 101, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Mapping; Brain Neoplasms; Choline; Cohor	2004
Treatment of severe pediatric ethylene glycol intoxication without hemodialysis. Journal of toxicology. Clinical toxicology, 2004, Volume: 42, Issue:3 Topics: Acidosis; Adolescent; Antidotes; Bicarbonates; Child; Creatine; Disease Progression; Ethylene Glycol	2004
Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Adult; Aspartic Acid; Cerebellum; Cerebral Cortex; Choline; Creatine; Disease Progression; Female; H	2004
Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. Journal of neuro-oncology, 2005, Volume: 71, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aspartic Acid; Central Nervous Syst	2005
Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology, 2005, Feb-08, Volume: 64, Issue:3 Topics: Adolescent; Adrenoleukodystrophy; Aspartic Acid; Brain Chemistry; Child; Child, Preschool; Creatine;	2005
Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. International journal of radiation oncology, biology, physics, 2005, May-01, Volume: 62, Issue:1 Topics: Aspartic Acid; Brain Stem Neoplasms; Child; Child, Preschool; Choline; Creatine; Disease Progression	2005
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiology of aging, 2006, Volume: 27, Issue:7 Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis	2006
Progressive intestinal, neurological and psychiatric problems in two adult males with cerebral creatine deficiency caused by an SLC6A8 mutation. Clinical genetics, 2005, Volume: 68, Issue:4 Topics: Aged; Amino Acid Transport Disorders, Inborn; Brain; Creatine; Depression; Disease Progression; Fema	2005
Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron. Clinical practice, 2006, Volume: 102, Issue:1 Topics: Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; C-Reactive Protein; Creatine; Cyclo	2006
Turbulence of glomerular hemodynamics involved in progressive glomerulosclerosis. Kidney international, 2006, Volume: 69, Issue:10 Topics: Albumins; Animals; Antibodies, Monoclonal; Blood Proteins; Blood Urea Nitrogen; Cholesterol; Creatin	2006
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of aging, 2007, Volume: 28, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Choline; Cognition	2007
Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy. Kidney & blood pressure research, 2006, Volume: 29, Issue:5 Topics: Aged; Blood Pressure; Cholesterol; Creatine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabe	2006
MRI and MRS alterations in the preclinical phase of murine prion disease: association with neuropathological and behavioural changes. Neurobiology of disease, 2007, Volume: 26, Issue:3 Topics: Animals; Aspartic Acid; Astrocytes; Body Water; Brain; Choline; Creatine; Diffusion; Disease Models,	2007
Time course of early metabolic changes following diffuse traumatic brain injury in rats as detected by (1)H NMR spectroscopy. Journal of neurotrauma, 2007, Volume: 24, Issue:6 Topics: Amino Acids; Animals; Aspartic Acid; Brain; Brain Chemistry; Brain Injuries; Creatine; Diffuse Axona	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Creatine; Disease Progression; Female;	2007
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American journal of hematology, 2008, Volume: 83, Issue:1 Topics: Adult; Anemia, Sickle Cell; Creatine; Disease Progression; Female; Follow-Up Studies; Humans; Hypert	2008
Monovoxel 1H magnetic resonance spectroscopy in the progression of gliomas. European neurology, 2007, Volume: 58, Issue:4 Topics: Adult; Aged; Aspartic Acid; Brain Neoplasms; Choline; Creatine; Disease Progression; Female; Glioma;	2007
Early and sustained alterations in cerebral metabolism after traumatic brain injury in immature rats. Journal of neurotrauma, 2008, Volume: 25, Issue:6 Topics: Aging; Alanine; Animals; Animals, Newborn; Aspartic Acid; Brain; Brain Injuries; Cell Respiration; C	2008
Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma. The FEBS journal, 2008, Volume: 275, Issue:12 Topics: Adenocarcinoma; Animals; Cell Transformation, Neoplastic; Colorectal Neoplasms; Creatine; Creatine K	2008
Imaging of axonal damage in vivo in Rasmussen's syndrome. Brain : a journal of neurology, 1995, Volume: 118 ( Pt 3) Topics: Adolescent; Aspartic Acid; Brain Chemistry; Child; Chronic Disease; Creatine; Disease Progression; E	1995
Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure. American journal of nephrology, 1996, Volume: 16, Issue:2 Topics: Administration, Oral; Adsorption; Carbon; Combined Modality Therapy; Creatine; Creatinine; Diet, Pro	1996
Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients. NMR in biomedicine, 1996, Volume: 9, Issue:8 Topics: Aspartic Acid; Brain; Creatine; Disease Progression; Humans; Image Interpretation, Computer-Assisted	1996
Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. Journal of neurosurgery, 1997, Volume: 87, Issue:4 Topics: Adult; Aged; Aspartic Acid; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cell Transformation, Neoplas	1997
Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. Journal of neurosurgery, 1997, Volume: 87, Issue:4 Topics: Aspartic Acid; Brachytherapy; Brain; Brain Neoplasms; Choline; Contrast Media; Creatine; Disease Pro	1997
Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR. American journal of neuroradiology, 1998, Volume: 19, Issue:2 Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Disease Progression; Female; Follow-Up Studies; Huma	1998
Proton magnetic resonance spectroscopy of linear nevus sebaceus syndrome. Pediatric neurology, 1998, Volume: 18, Issue:2 Topics: Aspartic Acid; Brain Chemistry; Cerebral Cortex; Child, Preschool; Choline; Creatine; Disease Progre	1998
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain : a journal of neurology, 1998, Volume: 121 ( Pt 8) Topics: Aspartic Acid; Axons; Brain; Creatine; Disability Evaluation; Disease Progression; Humans; Longitudi	1998
Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration. Journal of neuroimaging : official journal of the American Society of Neuroimaging, 1999, Volume: 9, Issue:2 Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Disease Pro	1999
Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1999, Volume: 33, Issue:6 Topics: Adult; Creatine; Disease Progression; Female; Genotype; Glomerulonephritis, IGA; Humans; Hypertensio	1999
Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Italian journal of neurological sciences, 1999, Volume: 20, Issue:4 Topics: Adult; Aged; Aspartic Acid; Brain; Choline; Creatine; Diagnosis, Differential; Disease Progression;	1999
MR spectroscopy in gliomatosis cerebri. AJNR. American journal of neuroradiology, 2000, Volume: 21, Issue:2 Topics: Adolescent; Adult; Aged; Aspartic Acid; Biopsy; Brain; Brain Neoplasms; Child; Choline; Creatine; Di	2000
Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR in biomedicine, 2000, Volume: 13, Issue:2 Topics: Adult; Aged; Aspartic Acid; Brain; Choline; Creatine; Disease Progression; Female; Humans; Magnetic	2000
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology, 2000, Jul-25, Volume: 55, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde	2000
Magnetic resonance spectroscopy of tubers in patients with tuberous sclerosis. Acta neurologica Scandinavica, 2000, Volume: 102, Issue:3 Topics: Adult; Age Factors; Aspartic Acid; Case-Control Studies; Child; Child, Preschool; Creatine; Disease	2000
Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:1 Topics: Administration, Oral; Animals; Creatine; Dietary Supplements; Disease Progression; Female; Humans; K	2001
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Archives of neurology, 2001, Volume: 58, Issue:1 Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Chromatography, High Pressure Liquid; Creatine; Disabil	2001
Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clinical and experimental hypertension (New York, N.Y. : 1993), 2001, Volume: 23, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B	2001
Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Archives of neurology, 2001, Volume: 58, Issue:5 Topics: Adult; Amyotrophic Lateral Sclerosis; Aspartic Acid; Choline; Creatine; Disease Progression; Female;	2001
Correlation of cerebral metabolites with clinical outcome among patients with severe congestive heart failure. Circulation, 2001, Jun-12, Volume: 103, Issue:23 Topics: Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Disease Progression; Heart Failure; Hu	2001
Severe metabolic abnormalities in the white matter of patients with vacuolating megalencephalic leukoencephalopathy with subcortical cysts. A proton MR spectroscopic imaging study. Journal of neurology, 2001, Volume: 248, Issue:5 Topics: Adolescent; Adult; Aspartic Acid; Creatine; Cysts; Dementia, Vascular; Disease Progression; Female;	2001
Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, Volume: 1, Issue:3 Topics: Administration, Oral; Animals; Cell Count; Creatine; Disease Models, Animal; Disease Progression; Fo	2000
Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology, 2002, Mar-12, Volume: 58, Issue:5 Topics: Amyotrophic Lateral Sclerosis; Aspartic Acid; Choline; Creatine; Disease Progression; Female; Humans	2002

creatine and Disease Exacerbation